Denali Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DNLI Nasdaq 2836 www.denalitherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Denali Therapeutics Inc.

Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out' - May 9th, 2026 4:00 am
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - May 7th, 2026 2:01 pm
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - May 5th, 2026 2:53 pm
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - May 4th, 2026 12:08 am
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive? - May 2nd, 2026 12:31 pm
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in - Apr 29th, 2026 7:17 am
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform - Apr 23rd, 2026 12:37 am
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? - Apr 17th, 2026 11:38 am
A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And Zasocitinib - Apr 8th, 2026 1:08 pm
Denali Stock Falls as Partner Takeda Ends Collaboration Deal - Apr 7th, 2026 12:27 pm
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - Apr 3rd, 2026 11:30 am
Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying. - Apr 1st, 2026 6:01 am
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's Changed - Mar 29th, 2026 11:03 pm
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Mar 26th, 2026 12:25 pm
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost - Mar 25th, 2026 3:05 pm
Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval - Mar 25th, 2026 2:08 pm
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - Mar 25th, 2026 9:50 am
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts - Mar 19th, 2026 8:56 am
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build - Mar 15th, 2026 5:12 am
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Mar 13th, 2026 2:08 pm